Citizens maintains Market Outperform rating on AtriCure, $68 price target

BlackRock reported a 15.4% ownership stake in AtriCure (ATRC), with sole voting and dispositive power over 7.8 million shares. The report also noted that iShares Core S&P Small-Cap ETF has an interest in more than 5% of AtriCure's outstanding common stock.

Analysts downgraded several companies: Foghorn Therapeutics (FHTX) to Neutral, First Busey (BUSE) to Neutral with a $30 target, AST SpaceMobile (ASTS) to Neutral with a $65 target, AtriCure (ATRC) to Hold with a $57 target, and Equity Bancshares (EQBK) to Neutral with a $52 target. ASTS closed at $57.04 on Thursday.

Freedom Capital Markets downgraded AtriCure to Hold with a $57.00 price target, implying 6.4% upside. Concerns include overvaluation and uncertainty in clinical data, according to the analyst note.

Several biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.

Piper Sandler maintained its Overweight rating for AtriCure (ATRC) and raised its price target from $50.00 to $60.00. The company's stock is currently trading at $48.16, which GuruFocus deems 21.6% overvalued. AtriCure has a GF Score of 79/100, indicating strong overall performance, but significant insider selling has occurred recently.

Piper Sandler raised its price target for AtriCure (NASDAQ:ATRC) to $60, citing a new quality measure for atrial fibrillation treatment as a catalyst. The firm expects market penetration to increase, driving growth. AtriCure's Q2 2026 earnings beat estimates, but shares fell on cautious outlook. BTIG also raised its target to $55.